Efficacy and Safety of NNC 0078-0000-0007 in Treatment of Acute Bleeding Episodes in Patients with Congenital Haemophilia and Inhibitors
This study is funded by Novo Nordisk, Inc. The purpose of this Phase III clinical trial is to see if a new drug (rFVII analogue) can treat bleeding in patients with haemophilia A or B and inhibitors. Patients that choose to participate in this trial will receive both the rFVIIa analogue and NovoSeven. NovoSeven is currently used to treat bleeding in haemophilia A and B patients with inhibitors.
A Multi-Centre, Open-Label, Single-Arm, and Multiple Dosing Trial on Safety of Monthly Replacement Therapy with Recombinant Factor XIII (rFXIII) in Subjects with Congenital Factor XIII Deficiency
This study is funded by Novo Nordisk, Inc. The purpose of this The purpose of this Phase III clinical trial is to find out if a recombinant Factor XIII product is safe and can prevent uncontrolled bleeding in patients with congenital FXIII deficiency.
Universal Data and Serum Collection Study (UDC) sponsored by the Centers for Disease Control and Prevention has been enrolling patients since 1998 to monitor the health status of persons with hemophilia and related bleeding disorders. Enrolling now.
Universal Data Collection for Blood Inhibitors Study has been enrolling since 2005. The purpose of the study is to identify factors that increase the risk of developing an inhibitor to factor concentrate. Our target is to enroll and maintain 50 patients with hemophilia A or B on the study. The study is funded through the Centers for Disease Control Foundation. Enrolling now.
Correlation between Vitamin D status and Bone Mineral Density in Patients with Hemophilia A will begin enrollment in the fall of 2009. This study is funded by the CSL Behring Foundation. A pilot study at our center demonstrated that about 60 percent of our children with hemophilia have vitamin D deficiency. This study seeks to understand whether vitamin D deficiency is an independent risk factor leading to low bone mass. Enrolling now.
Mechanisms of Race-based Differences in Factor VIII Immunogenicity in Hemophilia is a NIH funded study is designed to help better understand why African Americans with hemophilia A have a higher rate of inhibitor development. This study will begin in the spring of 2010.
A randomized controlled trial of enoxaparin thromboprophylaxis in cancer patients with elevated tissue factor bearing microparticles. Principal Investigator: Jeffrey Zwicker, M.D., (Beth Israel Deaconess Medical Center). This study will begin in the spring of 2010.
ATHN Data Quality Counts: This funding supports a data coordinator for the purposes of maintaining core data for the American Thrombosis and Hemostasis Network. Funding began January 2010.
PK-PD Study of Factor VIII Levels and Global Hemostasis Biomarkers in Hemophilia: This study is funded through an AD Williams grant to ascertain the relationship between Factor VIII levels, platelet function and thrombin generation effects in patients receiving factor concentrate to assist in the development of patient-specific FVIII prophylactic dosing.